Endo International PLC (ENDP) Price Target Lowered to $7.00 at Citigroup Inc.
A number of other equities research analysts have also recently issued reports on ENDP. Goldman Sachs Group, Inc. (The) initiated coverage on shares of Endo International PLC in a report on Thursday, September 28th. They issued a sell rating and a $7.00 price objective for the company. Royal Bank Of Canada decreased their price objective on shares of Endo International PLC from $9.00 to $8.00 and set a sector perform rating for the company in a report on Friday. Piper Jaffray Companies reiterated a hold rating and issued a $9.00 price objective on shares of Endo International PLC in a report on Sunday, September 17th. Mizuho reiterated a buy rating and issued a $14.00 price objective (down from $19.00) on shares of Endo International PLC in a report on Tuesday, September 12th. Finally, Oppenheimer Holdings, Inc. reiterated a hold rating on shares of Endo International PLC in a report on Tuesday, August 8th. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating and five have assigned a buy rating to the company. Endo International PLC has an average rating of Hold and a consensus target price of $11.67.
Endo International PLC (ENDP) traded up $0.84 during trading on Friday, hitting $6.93. 12,136,900 shares of the stock traded hands, compared to its average volume of 7,342,927. The company has a debt-to-equity ratio of 10.78, a quick ratio of 0.86 and a current ratio of 1.08. Endo International PLC has a fifty-two week low of $5.77 and a fifty-two week high of $18.63. The stock has a market cap of $1,550.00, a PE ratio of 1.43 and a beta of 0.53.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings results on Thursday, November 9th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.85 by $0.06. Endo International PLC had a negative net margin of 126.97% and a positive return on equity of 66.98%. The business had revenue of $786.90 million for the quarter, compared to analysts’ expectations of $794.93 million. During the same period in the previous year, the company posted $1.01 EPS. Endo International PLC’s revenue was down 11.0% on a year-over-year basis. research analysts anticipate that Endo International PLC will post 3.54 earnings per share for the current year.
WARNING: This article was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/11/13/endo-international-plc-endp-price-target-lowered-to-7-00-at-citigroup-inc.html.
In other news, CFO Blaise Coleman acquired 6,500 shares of the company’s stock in a transaction dated Tuesday, August 15th. The stock was bought at an average price of $7.89 per share, with a total value of $51,285.00. Following the completion of the acquisition, the chief financial officer now owns 13,729 shares in the company, valued at approximately $108,321.81. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.50% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. James Investment Research Inc. acquired a new stake in shares of Endo International PLC during the second quarter worth approximately $113,000. Blair William & Co. IL bought a new stake in shares of Endo International PLC during the second quarter valued at approximately $126,000. Point View Wealth Management Inc. grew its stake in shares of Endo International PLC by 16.6% during the second quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock valued at $149,000 after purchasing an additional 1,900 shares during the last quarter. Riverhead Capital Management LLC grew its stake in shares of Endo International PLC by 64.4% during the second quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after purchasing an additional 5,887 shares during the last quarter. Finally, Bank of Hawaii bought a new stake in shares of Endo International PLC during the second quarter valued at approximately $180,000. 90.50% of the stock is owned by institutional investors.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.